> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letters
- URL: https://www.fdaweb.com/latest-fda-warning-letters-47/
- Published: 2020-12-08T12:00:00.000Z
- Updated: 2026-09-14T16:39:14.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148256

FDA has posted its latest batch of Warning Letters. They can be accessed by clicking on the link following each letter.  

**Natures Boost**, Kirkland, WA (11/20): A recent FDA review of the company’s Web site determined that it is marketing two unapproved new drugs in violation of the Federal Food, Drug, and Cosmetic Act. The agency letter provides some of the promotional statements from the Web site that establish that the products are intended for use in the cure, mitigation, treatment, or prevention of disease. It also says the products are misbranded. To view the Warning Letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natures-boost-llc-609846-11202020?ref=fdaweb.com).  

**Valentus, Inc.**, Sioux Falls, SD (11/30): FDA recently reviewed the company’s Web site and determined that it takes orders for several products that the Federal Food, Drug, and Cosmetic Act considers to be unapproved new drugs because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The letter gives examples of the Web site statements that establish that the products are legally considered to be drugs. The letter also says the products are misbranded. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/valentus-inc-609611-11302020?ref=fdaweb.com).